Ambrx Biopharma Quarterly Balance Sheets Chart
Quarterly
|
Annual
Ambrx Biopharma Quarterly Balance Sheets Table
Quarterly
|
Annual
| Unit: USD | 2023-06-30 | 2023-03-31 | 2022-12-31 |
|---|---|---|---|
| assets | |||
| current assets: | |||
| cash and cash equivalents | 228,265,000 | 149,584,000 | 55,610,000 |
| restricted cash | 665,000 | 665,000 | 831,000 |
| marketable debt securities, available-for-sale | 6,824,000 | 7,940,000 | 28,873,000 |
| accounts receivable | 81,000 | 62,000 | 376,000 |
| prepaid expenses and other current assets | 5,578,000 | 4,691,000 | 4,893,000 |
| total current assets | 241,413,000 | 162,942,000 | 90,583,000 |
| marketable debt securities, available-for-sale, net of current portion | 8,798,000 | 16,793,000 | |
| property and equipment | 3,195,000 | 2,889,000 | 3,044,000 |
| right-of-use assets | 10,044,000 | 10,511,000 | 10,968,000 |
| intangible assets | 24,935,000 | 25,093,000 | 25,250,000 |
| other long-term assets | 357,000 | 380,000 | 339,000 |
| total assets | 279,944,000 | 210,613,000 | 146,977,000 |
| liabilities and shareholders' equity | |||
| current liabilities: | |||
| accounts payable | 6,362,000 | 7,107,000 | 3,205,000 |
| accrued liabilities | 9,556,000 | 6,782,000 | 11,314,000 |
| operating lease liabilities, current portion | 1,854,000 | 1,793,000 | 1,734,000 |
| deferred revenue, current portion | 407,000 | 407,000 | 407,000 |
| total current liabilities | 18,179,000 | 16,089,000 | 16,660,000 |
| operating lease liabilities, net of current portion | 9,163,000 | 9,710,000 | 10,245,000 |
| deferred tax liabilities | 880,000 | 880,000 | 880,000 |
| deferred revenue, net of current portion | 1,342,000 | 1,342,000 | 1,342,000 |
| total liabilities | 29,564,000 | 28,021,000 | 29,127,000 |
| commitments and contingencies | |||
| shareholders' equity | |||
| ordinary shares, par value 0.0001; 950,000,000 and 500,000,000 shares authorized at june 30, 2023 and december 31, 2022, respectively; 432,227,488 and 270,455,232 shares issued and outstanding at june 30, 2023 and december 31, 2022, respectively | 43,000 | ||
| additional paid-in capital | 576,046,000 | 490,459,000 | 410,753,000 |
| accumulated other comprehensive loss | -953,000 | -976,000 | -1,302,000 |
| accumulated deficit | -324,756,000 | -306,930,000 | -291,628,000 |
| total shareholders' equity | 250,380,000 | 182,592,000 | 117,850,000 |
| total liabilities and shareholders' equity | 279,944,000 | 210,613,000 | 146,977,000 |
| ordinary shares, par value 0.0001; 600,000,000 and 500,000,000 shares authorized at march 31, 2023 and december 31, 2022, respectively; 386,486,014 and 270,455,232 shares issued and outstanding at march 31, 2023 and december 31, 2022, respectively | 39,000 | ||
| ordinary shares, par value 0.0001; 500,000,000 shares authorized at december 31, 2022 and 2021; 270,455,232 and 270,120,548 shares issued and outstanding as of december 31, 2022 and 2021, respectively | 27,000 |
We provide you with 20 years of balance sheets for Ambrx Biopharma stock, allowing you to gain comprehensive visibility into the fundamentals of the company. Our detailed breakdowns include key financial metrics such as asset and liabilities, payables and receivables, long debts and short debts, cash and inventories, expenses and profits. This in-depth information is essential for making informed investment decisions and understanding the financial health and performance of Ambrx Biopharma. Explore the full financial landscape of Ambrx Biopharma stock with our expertly curated balance sheets.
The information provided in this report about Ambrx Biopharma stock is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.